Wells Fargo & Company Cuts ResMed (NYSE:RMD) Price Target to $215.00

ResMed (NYSE:RMD) had its price objective reduced by Wells Fargo & Company from $225.00 to $215.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective points to a potential upside of 1.68% from the stock’s current price.

RMD has been the topic of several other research reports. Evercore set a $255.00 price objective on ResMed and gave the stock an “outperform” rating in a research note on Monday, April 13th. The Goldman Sachs Group reiterated a “buy” rating on shares of ResMed in a research note on Wednesday, July 1st. Jefferies Financial Group reduced their target price on shares of ResMed from $240.00 to $225.00 and set a “hold” rating for the company in a report on Friday, July 10th. Weiss Ratings cut shares of ResMed from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, July 24th. Finally, UBS Group reaffirmed a “buy” rating and set a $300.00 price target on shares of ResMed in a report on Tuesday, July 21st. Seven analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, ResMed currently has an average rating of “Hold” and a consensus target price of $244.50.

ResMed Stock Performance

Shares of NYSE:RMD traded down $11.79 during midday trading on Friday, hitting $211.45. The company had a trading volume of 624,182 shares, compared to its average volume of 1,285,624. ResMed has a 12-month low of $180.26 and a 12-month high of $293.81. The company has a fifty day moving average of $200.06 and a two-hundred day moving average of $222.30. The company has a market cap of $30.67 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.36 and a beta of 0.76. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33.

ResMed (NYSE:RMD) last released its earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.89 by $0.06. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.46 billion. During the same period in the previous year, the business earned $2.55 earnings per share. ResMed’s quarterly revenue was up 8.6% compared to the same quarter last year. On average, equities research analysts expect that ResMed will post 11.14 EPS for the current fiscal year.

Insider Activity

In other news, Director Peter C. Farrell sold 8,000 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $225.00, for a total value of $1,800,000.00. Following the transaction, the director directly owned 52,773 shares in the company, valued at $11,873,925. The trade was a 13.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $218.55, for a total value of $1,090,783.05. Following the completion of the transaction, the chief executive officer directly owned 466,223 shares of the company’s stock, valued at approximately $101,893,036.65. This trade represents a 1.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 17,982 shares of company stock worth $3,858,837 over the last 90 days. Company insiders own 0.65% of the company’s stock.

Institutional Investors Weigh In On ResMed

A number of institutional investors have recently added to or reduced their stakes in RMD. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of ResMed during the second quarter valued at approximately $68,376,000. Plato Investment Management Ltd bought a new position in shares of ResMed during the second quarter worth $668,000. Bell Investment Advisors Inc bought a new position in shares of ResMed during the second quarter worth $26,000. Simplicity Wealth LLC purchased a new position in ResMed during the second quarter valued at $239,000. Finally, Flputnam Investment Management Co. purchased a new position in ResMed during the second quarter valued at $1,044,000. 54.98% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal Q4 earnings of $2.95 per share, above analyst expectations of approximately $2.89–$2.90 and up from $2.55 a year earlier. Revenue rose 8.6% year over year to $1.46 billion, supporting the company’s continued growth. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company raised its dividend alongside its strong fourth-quarter and full-year fiscal 2026 results, potentially increasing its appeal to income-focused investors. ResMed Posts Strong Q4 Earnings and Lifts Dividend
• Neutral Sentiment: Analyst opinion remains cautious. ResMed has an average “Hold” rating, with several firms recently reducing price targets, although the consensus target of $246.25 remains above the current trading level. ResMed Receives Average Hold Rating
• Neutral Sentiment: Investors are also weighing industry risks, including tariffs, inflation and pressure on hospital spending, which could affect medtech demand and margins despite ResMed’s profitability. Medtech Earnings Season Preview
• Negative Sentiment: Director Peter Farrell sold 8,000 shares for $1.8 million, reducing his stake by 13.16%. Because the sale occurred under a pre-arranged Rule 10b5-1 plan, it is a limited signal of insider confidence, but it may still create modest selling pressure. SEC Insider Trading Filing

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.